Comparison of Transarterial Chemoembolization in Patients With Unresectable, Diffuse vs Focal Hepatocellular Carcinoma
Authors:
- Shi-Hui PanShi-Hui Pan
- Allen L. HoffmanAHAllen L. Hoffman
- Carlos RamirezCRCarlos Ramirez
- Sergio E. RojterSRSergio E. Rojter
- Hector RamosHRHector Ramos
- Michael McMonigleMMMichael McMonigle
- Juan LoisJLJuan Lois
Open Access
- 1 June 2002
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 137 (6) , 653-658
Abstract
HEPATOCELLULAR carcinoma (HCC) is one of the most common malignant tumors worldwide. Viral hepatitis B and C infections and cirrhosis are known risk factors.1 Most patients are diagnosed as having HCC late and have underlying liver disease that often precludes effective treatment. These patients have a poor prognosis and most will live less than 1 year after diagnosis.2Keywords
This publication has 1 reference indexed in Scilit: